Search

Your search keyword '"V, Pengo"' showing total 48 results

Search Constraints

Start Over You searched for: Author "V, Pengo" Remove constraint Author: "V, Pengo" Region italy Remove constraint Region: italy
48 results on '"V, Pengo"'

Search Results

1. The use of reduced DOAC doses in atrial fibrillation patients does not always lead to good anticoagulation levels and avoid adverse events.

2. Low platelet count at admission has an adverse impact on outcome in patients with acute coronary syndromes: from the START Antiplatelet registry.

3. Gender Related Differences in Gastrointestinal Bleeding With Oral Anticoagulation in Atrial Fibrillation.

4. Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome.

5. [Concepts and preconceptions on the use of direct oral anticoagulants in Italy: a Delphi consensus panel of the Atherosclerosis Thrombosis, Vascular Biology Study Group (ATBV)].

6. Reduction in all-cause mortality in COVID-19 patients on chronic oral anticoagulation: A population-based propensity score matched study.

7. Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry.

8. Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure.

9. Questions and Answers on Practical Thrombotic Issues in SARS-CoV-2 Infection: A Guidance Document from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology.

10. [Antithrombotic treatments in patients with SARS-CoV-2 infection: from current evidence to reasonable recommendations - A position paper from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology].

11. Death rates and causes in anticoagulated atrial fibrillation patients: a population-based study.

12. Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry).

13. Real-world persistence with direct oral anticoagulants (DOACs) in naïve patients with non-valvular atrial fibrillation.

14. Antiplatelet treatment in acute coronary syndrome patients: Real-world data from the START-Antiplatelet Italian Registry.

15. Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants.

16. Epidemiology and Management of Patients With Acute Coronary Syndromes in Contemporary Real-World Practice: Evolving Trends From the EYESHOT Study to the START-ANTIPLATELET Registry.

17. Risk factors for intracranial hemorrhage during vitamin K antagonist therapy in patients with nonvalvular atrial fibrillation: A case-control study.

18. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.

19. Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study.

20. Impact of Chronic Renal Failure on Ischemic and Bleeding Events at 1 Year in Patients With Acute Coronary Syndrome (from the Multicenter START ANTIPLATELET Registry).

21. Different safety profiles of oral anticoagulants in very elderly non-valvular atrial fibrillation patients. A retrospective propensity score matched cohort study.

22. Cancer as a risk factor for stroke in atrial fibrillation patients receiving long-term oral anticoagulant therapy.

23. The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation.

24. Artificial nutrition and hydration in terminally ill patients with advanced dementia: opinions and correlates among Italian physicians and nurses.

25. [A Censis survey on atrial fibrillation awareness in the general population and among general practitioners and affected patients in Italy].

26. Physicians' and nurses' experiences of end-of-life decision-making in geriatric settings.

27. Management of special conditions in patients on vitamin K antagonists.

28. Biological variation of INR in stable patients on long-term anticoagulation with warfarin.

29. The negative predictive value of D-dimer on the risk of recurrent venous thromboembolism in patients with multiple previous events: a prospective cohort study (the PROLONG PLUS study).

30. Family history of venous thrombosis or sudden death as a risk factor for venous thromboembolism.

31. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA).

32. Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study.

33. Long-term use of vitamin K antagonists and incidence of cancer: a population-based study.

34. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome.

35. Prevalence of heart diseases in patients with pulmonary embolism with and without peripheral venous thrombosis: findings from a cross-sectional survey.

36. Management of patients on long-term oral anticoagulant therapy undergoing elective surgery: survey of the clinical practice in the Italian anticoagulation clinics.

37. A comparison of lupus anticoagulant-positive patients with clinical picture of antiphospholipid syndrome and those without.

38. Knowledges about herbal products among subjects on warfarin therapy and patient-physician relationship: a pilot study.

39. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM).

42. Lupus anticoagulant (LA) testing: performance of clinical laboratories assessed by a national survey using lyophilized affinity-purified immunoglobulin with LA activity.

43. Assessment of patient capability to self-adjust oral anticoagulant dose: a multicenter study on home use of portable prothrombin time monitor (COAGUCHECK).

44. Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study.

45. Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study: ISCOAT study group (Italian Study on Complications of Oral Anticoagulant Therapy).

46. [Hemorrhagic complications of oral anticoagulant therapy: results of a prospective multicenter study ISCOAT (Italian Study on Complications of Oral Anticoagulant Therapy)].

47. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy.

48. [Advantages of a cardiologic ambulatory care facility specifically organized for patients undergoing treatment with oral anticoagulant drugs].

Catalog

Books, media, physical & digital resources